CompletedPHASE1, PHASE2NCT01926587
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Studying Chronic myelomonocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Traws Pharma, Inc.
- Principal Investigator
- Steven M. Fruchtman, MDTraws Pharma, Inc.
- Intervention
- oral rigosertib(drug)
- Enrollment
- 45 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2013 – 2021
Study locations (13)
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- City of Hope, Duarte, California, United States
- Desert Hematology Oncology Medical Group, Inc., Rancho Mirage, California, United States
- Rush University Medical Center, Chicago, Illinois, United States
- Cancer Center of Kansas, Wichita, Kansas, United States
- Saint Louis University, St Louis, Missouri, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- Mount Sinai Medical Center, New York, New York, United States
- White Plains Hospital Center for Cancer Care, White Plains, New York, United States
- Carolina Blood and Cancer Care Associates, Rock Hill, South Carolina, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
- Hôpital St. Louis, Paris, France
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01926587 on ClinicalTrials.govOther trials for Chronic myelomonocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07071155Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic LeukemiaSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- RECRUITINGNCT07512882Cohort of Patients With Chronic Myelomonocytic LeukemiaGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGPHASE2NCT06815003Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity ConditioningCity of Hope Medical Center
- RECRUITINGPHASE2NCT06597734A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative NeoplasmM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT06543381Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell TransplantCity of Hope Medical Center
- RECRUITINGPHASE3NCT06647862IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- RECRUITINGPHASE1, PHASE2NCT06159491Pacritinib in CMMLDouglas Tremblay
- RECRUITINGPHASE1NCT06218628Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionFox Chase Cancer Center